About Us
We are a preclinical stage bio-pharmaceutical company located in Paris
We are mission-driven, dedicated to advancing medicine, improving patients’ health and saving lives
We have the ambition to become a leading player in the market of rare kidney diseases in both adults and children
We are first focused on the treatment of Crescentic Glomerulonephritis in adults, a severe condition with no effective treatment
The company is lead by a seasoned and complementary leadership team with more than 130 years of experience in successfully bringing products on the market.
Backed by renowed clinical leaders in renal medicine and a large access to patients network, DETERA Therapeutics is well-positioned to advance its mission.
Lyse SANTORO- PhD & Insead
Co-Founder & CEO
The Executive Team
Daniel GILLET- PhD
Co-Founder & CSO/COO
Pierre-Louis THARAUX- MD, PhD
Co-Founder & CMO
André ULMANN- MD, PhD
Business Angel, Successful Serial Entrepreneur
Sharesholders
Alongisde founding leadership team members Lyse Santoro, Daniel Gillet, Pierre-Louis Tharaux, additional shareholders also contribute to DETERA’s strategic vision.
A network of Key Opinion Leaders
Guided by Global Experts , we are proud to be supported by world-renowed Key Opinion Leaders in the field of rare kidney diseases, particularly those affecting the glomeruli such as CGN and the conditions we study. Their commitment and expertise strenghthen our mission and accelerate our path toward transformative therapties.
